Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Rubicon Partners with Diagenode for ChIP Sample Preparation

Published: Monday, November 05, 2012
Last Updated: Sunday, November 04, 2012
Bookmark and Share
Combining Rubicon ThruPLEX™ and Diagenode technologies enables scientists to efficiently conduct high quality ChIP studies from small samples for NGS and array analysis.

Rubicon Genomics, Inc. has announced that it has partnered with Diagenode SA to integrate Rubicon’s ThruPLEX™ technology into Diagenode’s epigenetics platforms to increase the efficiency and quality of DNA sample preparation for chromatin immunoprecipitation (ChIP) applications.

The new agreement allows Diagenode to incorporate the Rubicon ThruPLEX-FD technology into its new MicroPLEX Library Preparation Kit for ChIP-seq studies requiring very small amounts of sample.

Rubicon is a leading provider of sample-specific pre-analytical processes to improve the performance and capabilities of DNA analytical platforms.

Its ThruPLEX-FD NGS Prep kits for synthesis and amplification of ChIP DNA for next generation sequencing (NGS) use a one-tube, three-step process that is efficient, fast, and produces high quality DNA from small samples.

Diagenode’s products increase the efficiency and speed of the process used to precipitate and recover DNA for ChIP applications from very small amounts of chromatin.

The combination of these two patented technologies will decrease the time and labor needed for ChIP-sequencing by almost 10 hours and provide researchers with high quality ChIP-seq and ChIP-chip results from small samples, reducing the number of cells needed to conduct ChIP analyses by a minimum of 100-fold.

“This partnership with Diagenode extends the reach of our proprietary technology. Diagenode is a leader in the ChIP market and our ThruPLEX technology is ideal for use in ChIP studies. This partnership is an important example of our collaboration strategy that focuses on combining complementary technologies to offer complete solutions to the research community,” noted James Koziarz, CEO of Rubicon Genomics.

Rubicon intends to complete additional non-exclusive distribution agreements with leaders in other segments of the growing market for DNA and RNA analysis.

Diagenode has developed and validated reagents and equipment that reduce the number of cells needed to conduct analyses by 10 to 100-fold.

This allows researchers to grow or harvest fewer cells, decreasing time and expense, and also enables studies of small subpopulations of cells.

Combining these properties with the advantages of ThruPLEX-FD increases the quality of the sequencing results and is expected to enhance the value of ChIP as a tool for epigenomic research.

“We are pleased to add the Rubicon ThruPLEX technology to Diagenode’s high quality product line for ChIP studies,” said Didier Allaer, CEO and Founder of Diagenode. “It’s fast, easy-to-use and sensitive, producing high quality results from challenging samples. We will also offer the MicroPLEX and True MicroChIP kits to our customers in conjunction with our new SX-8G IP-Star® Automated System, the first comprehensive system to automate ChIP and DNA methylation assays.”

Rubicon’s ThruPLEX technology incorporates a streamlined one-tube, three-step process without intermediate purifications, transfers, columns or gels. The reduced steps and material transfers decrease the likelihood of experimental variability, bias and contamination.

ThruPLEX technology is designed and validated for use with samples as small as 50 picograms of human DNA and can be used in plasma, FFPE, cDNA, ChIP and population studies.

The kits are currently available for sequencing on Illumina® HiSeq®, MiSeq® and Genome Analyzer instruments. The technology is also being developed for additional formats and platforms.

Both Rubicon and Diagenode will be exhibiting at the Annual Meeting of the American Society for Human Genetics to be held in San Francisco, CA, November 6-10, 2012.

To learn more about Rubicon’s ThruPLEX and its other sample-specific pre-analytical technologies, visit Booth #803, and to learn more about Diagenode’s technologies, visit Booth #406.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos